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Background: Idiopathic short stature (ISS) refers to short stature with no evident etiologies. The custom genome-
wide microarray specifically designed to cover height-related genes may be helpful to detect copy number
variations (CNVs) in ISS patients, which may be missed by the general microarray. The aim of the study was to
validate the applicability of the custom microarray and to analyze CNVs in Chinese ISS children.
Results: Sixty non-polymorphic CNVs were identified in 119 ISS patients. There were 13 small CNVs with a size
below 50 kb, accounting for 21.7 % of all the CNVs (13/60). Five pathogenic or possibly pathogenic CNVs were
detected in five patients, including deletions at 22q11.21, duplications at 4q11-q13.1, 4q12 and Yp11.32-p11.2.
Taking only the pathogenic variants into account, the diagnostic yield was 2.5 % (3/119). The TMEM165, POLR2B and
PDGFRA genes were analyzed as candidate genes. A 15 kb deletion in the RASA2 gene was of interest for further
investigation.
Conclusions: This study showed that the custom microarray is applicable to detect CNVs in patients with short
stature. Candidate genes and CNVs detected in ISS patients may be helpful for CNV analysis of short stature,
especially in East Asian population.
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Short stature is a common reason for referral to a
pediatric endocrine clinic. Although a thorough diagnos-
tic workup is performed including detailed medical his-
tory, physical examination, biochemical and radiologic
screening, no definite cause can be established in ap-
proximately 80 % children [1]. As height is a classic
polygenic trait, genetic testing consisting of target gene
sequencing and chromosome karyotype is the next step
if the clinician suspects a specific genetic disorder. How-
ever, a diagnosis of idiopathic short stature (ISS) is made
in most cases in the end. ISS is defined as a condition in
which the height of the individual is below 2 standard* Correspondence: yuyongguo@shsmu.edu.cn; gu_xuefan@163.com
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for a given age, sex and population group, and no
known causes can be found such as intrauterine
growth retardation, undernutrition, chronic pediatric
illness, growth hormone deficiency, and other dys-
morphic syndromes [2].
Chromosomal microarray (CMA), which has been rec-
ommended as the first-tier clinical diagnostic test for in-
dividuals with developmental disabilities or congenital
anomalies [3], has a much higher resolution than con-
ventional cytogenetic methods to screen genomic imbal-
ances and can better define the size. The imbalances
characterized by CMA are called copy number variations
(CNVs). A CNV refers to an imbalance of a genomic se-
quence that alters the diploid status of a particular locus
in the human genome. CNVs comprise deletions and du-
plications with DNA fragments ranging from 1 kilobaseistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Overview of the characteristics of the 119 patients
Feature
Total, n 119
Male/Female, n (%) 73(61.3)/46(38.7)
Age at the first evaluationa (years) 8.6 ± 3.4
SDS of length at birtha −0.40 ± 1.02
SDS of weight at birtha −0.24 ± 1.19
SDS of height at presentationa −2.96 ± 0.97
SDS standard deviation score
aThe value was shown as the mean ± standard deviation (SD)
Hu et al. Molecular Cytogenetics  (2016) 9:16 Page 2 of 7(kb) to several megabases (Mb) [4]. Rare CNVs, espe-
cially genomic deletions, were shown to be a contributor
to short stature [5, 6]. Recent studies showed that patho-
genic CNVs were found in 4–10 % of children referred
for short stature, indicating that CNV assessment cannot
be neglected for the evaluation of short stature without
apparent diagnostic clues [6, 7]. Although the outcomes
of these studies are promising, there are still some
underlying problems. First, some small pathogenic im-
balances may be missed. Although a CNV is defined to
be as small as 1 kb, most studies excluded the CNVs less
than 50 kb in consideration of the accuracy of diagnosis
[3, 7, 8], as most general CMA does not have sufficient
coverage to precisely call such small CNVs. Second, it is
difficult to identify the actual genes responsible for short
stature in large CNVs. In general, large CNVs are gene-
rich, and several genes may be associated with growth. It
is a great challenge to distinguish actual disease-causing
genes among them with limited information. In small
pathogenic CNVs with few genes, especially with only
one, it will be easier to find a new gene associated with
short stature for further study. The custom CMA de-
signed with target genes may be a better solution. In re-
cent years, some genome-wide association studies
(GWAS) for common variants in large populations of in-
dividuals have been performed to discover genomic loci
associated with height [9, 10]. More than 1077 candidate
genes have been considered to associate with height
[11]. However, the relationships between most of these
genes and height have not been well established since
there were few clinical reports.
In the present study, we firstly used the height-related
candidate genes to design a genome-wide CGH + SNP
microarray (CGH, comparative genomic hybridization;
SNP, single nucleotide polymorphism), and then per-
formed CNV detection in Chinese children with ISS in
an effort to validate the applicability of this custom
CMA as well as to reveal potential genes and loci related
to short stature.
Results
A total of 119 children from different families were in-
cluded in the present study. The cohort exhibited a male
predominance (61.3 %, 73/119). During the first evalu-
ation, the chronological age was 8.6 ± 3.4 years. The
mean SDS of length and weight at birth were −0.40 and
−0.24, respectively, which were within the normal range.
Postnatal growth restriction was obvious with the mean
SDS of height below −2 (Table 1).
Sxity non-polymorphic CNVs with the size ranging from
2 kb to 9 Mb were detected in 30 individuals after filtering
the raw data with the DGV database. There were 13 small
CNVs with the size below 50 kb, accounting for 21.7 %
(13/60) of the CNVs identified. A total of five rare CNVsthought to be pathogenic or possibly pathogenic were de-
tected in five patients, including two deletions and three
duplications (Additional file 1: Figure S1).
In type I CNVs, deletions at 22q11.2 were found in
two patients (patient 1 and 2) overlapping with the
known deletion syndrome (MIM 611867). Patient 3 had
a duplication containing partial SHOX gene that has
been considered to associate with ISS (MIM 300582).
Two type II CNVs were detected in patient 4 and 5 with
a duplication located in 4q11-q13.1 and 4q12, respect-
ively. Three genes, TMEM165, POLR2B and PDGFRA,
were considered as the height-related candidate genes
after searching supporting references. They were newly
identified genes associated with human height in GWAS
study and were all included in our target genes list. All
the genetic findings were summarized in Table 2.
Short stature was the only distinct symptom in the
majority of the patients according to the medical re-
cords. As to the patients carrying type I or II CNVs, de-
layed bone age was common. Other available clinical
information was shown in Table 3.
Only type III and IV CNVs or polymorphic CNVs were
found in the other 114 patients. As the CMA testing of
most parents and control group was not available, type
III and IV CNVs could not be clearly distinguished. At
last, all the CNVs categorized as benign or uncertain
significance were summarized in Additional file 1: Table
S2. A 15 kb deletion in the RASA2 gene was of potential
interest although it was classified into type III
(Additional file 1: Figure S1).
Taking only the pathogenic variants into account, the
overall diagnostic yield of CMA testing for patients with
ISS was 2.5 % (3/119).
Discussion
Short stature is a common symptom in a variety of
chromosome imbalances and monogenic disorders [12].
It is a challenge for clinicians to make a precise diagno-
sis relying on a general diagnostic workup such as stand-
ard physical examination and laboratory parameters that
assess the function of growth hormone axis. With tre-
mendous advance of techniques in genetic diagnostics
Table 2 Summary of type I and II CNVs
Patient Karyotypea Size (Mb) No. of genes DECIPHERb Syndrome Candidate gene
Type I
1 arr 22q11.21(18729944–21704972) × 1 3 64 19 22q11.2 TBX1
2 arr 22q11.21(20659547–21704972) × 1 1 21 16 22q11.2 -
3 arr Yp11.32-p11.2(545173–10045809) × 3 9.5 50 11 SHOX
Type II
4 arr 4q11-q13.1(52697788–59679060) × 3 7 39 0 - TMEM165, POLR2B
5 arr 4q12(54749407–55157199) × 3 0.4 4 0 - PDGFRA
aGenomic coordinates were based on Human Genome Building GCRh37, hg19
bNumber of overlapping CNVs reported in the DECIPHER database with the feature of postnatal-onset short stature
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etic evaluation has played a growing role in elucidating
the underlying causes of growth disorders. If a child is
diagnosed with ISS, CMA testing and next-generation
sequencing are recommended [13].
So far, there were only four studies in which CMA
testing was used to identify pathogenic CNVs in children
with short stature [6–8, 14]. Two of them involved in
children either born with normal birth size or born with
small for gestational age (SGA), and the other two con-
cerned the children born only with SGA. With the gen-
eral CMA, at least one disease-causing CNV was
detected in 4–10 % of patients without considering the
birth size and weight [13] or in ~16 % of patients born
with SGA [8, 14]. More studies are needed to explore
genetic etiologies on the chromosome level of unex-
plained short stature. In the present study, we performed
CMA testing in 119 patients with ISS using a custom
microarray. As a result, non-polymorphic CNVs with a
size as small as a few kb could be detected by our micro-
array. Among them, small CNVs with a size below 50 kb
accounted for 21.7 %, suggesting that small CNVs could
not be ignored for study. As these small CNVs were not
included in pathogenic or possibly pathogenic group,
they were not further validated by qPCR. The log2 ratio
used for CNV calling was very strict in the study, which
was produced from the practical measure of AgilentTable 3 Clinical information of patients with type I and II CNVs
Patient Gender Age (years) Height (cm), SDS Weight (kg) Clinical findin
Type I
1 M NA NA NA NA
2 M 7.8 110.8, −3.4 15.5 BA 4 years, B
3 M 7.3 115.3, −2.0 25.2 BA 6 years, B
Type II
4 M 16.3 152.8, −3.1 43 BA 13 years,
5 M 11.3 128, −2.8 21 BA 6 years, B
M male, SDS standard deviation score, BA bone age, BMI body mass index, NA not aCompany, thus most of the small CNVs were likely to be
true.
In the present study, the size of CNVs thought to be
pathogenic or possibly pathogenic was more than 400 kb
with a diagnostic yield of 2.5 % among children with ISS.
The frequency was low compared with previous reports.
This outcome was reasonable. Analyzing the previous
four studies, we found that pathogenic CNVs seemed to
be more common in patients born with SGA than in pa-
tients born with normal length and weight. In addition,
the diagnostic yield in the present study was calculated
taking only the pathogenic variants (type I CNVs) into
account. All the pathogenic CNVs were assessed based
on several supporting literatures, indicating that the
pathogenicity of these CNVs was widely received. There-
fore, our results demonstrated the applicability of the
custom CMA to detect CNVs, especially those with
small size. For instance, a 15 kb intragenic deletion in
the RASA2 gene, which was included in our target genes
list, was detected and was validated to be true. In a pre-
vious study [6], rare CNVs were further filtered with
control group after excluding polymorphic CNVs in the
DGV database, and all the CNVs smaller than 50 kb
were not retained. While in our study, 13 CNVs with a
size below 50 kb were retained after exclusion of poly-
morphic variants in the DGV database, indicating that a
further filtration with control group was necessary.gs
MI 12.6, normal heights of parents
MI 18.9, normal heights of parents
BMI 18.4, multiple pigmented nevi on the face, normal heights of parents
MI 12.8, ptosis, normal heights of parents
vailable
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pathogenicity of CNVs detected in East Asian popula-
tion. Although many CNVs in the study cannot establish
the association with short stature at present, several
identified CNVs, especially some small ones, may be
helpful for future studies.
The 22p11.21 deletions were found in two patients
(patient 1 and 2). These interstitial deletions were part
of the chromosome 22q11.2 deletion syndrome (MIM
611867, chr22:17,900,000-25,900,000, hg19). This dele-
tion syndrome was very common with an estimated fre-
quency of 1:2000–1:4000 [15]. There were many possible
signs and symptoms that might affect almost any aspect
of the body. Growth restriction was often found when a
deletion was involved this region [7, 8, 14, 16, 17]. The
22q11.2 microdeletions varied in size between ~700 kb
and ~3.6 Mb [16, 18]. According to the new proposed
categorization system [16], the region of 22q11.2 could
be divided into eight critical components named LCR22-
A to H (LCR, low copy repeat). The region of LCR22-A
to –D was assigned as the proximal 22q11.2 region
with ~3 Mb in size and the distal 22q11.2 region
comprised LCR22-D to –H. Deletion of the proximal
region presented the clinical manifestations of the re-
current DiGeorge/Velocardiofacial syndrome (DGS/
VCFS) (MIM 188400 and 192430). Haploinsufficiency
of the TBX1 gene in particular was responsible for
most of the physical malformations of these two syn-
dromes. In our study, the ~3.0 Mb deletion in patient
1 was the typical DGS/VCFS region containing the
TBX1 gene. Unfortunately, the outpatient medical re-
cords of the patient were lost and no more clinical
information could be reviewed. In patient 2, the
22q11.21 deletion was located in the proximal
22q11.2 region spanning LCR-B to –D in which the
TBX1 gene was not included. Growth restriction was
the only clinical phenotype in patient 2. It has been
reported in previous study that similar growth restric-
tion was the only phenotype [7].
A 9.5 Mb duplication containing part of the SHOX
gene in chromosome Y was detected in patient 3. One
copy of the SHOX gene is located on each of the sex
chromosomes (the X and Y chromosomes) in an area
called the pseudoautosomal region. Although many
genes are unique to either the X or Y chromosome,
genes in the pseudoautosomal region are present on
both chromosomes. As a result, both females (who have
two X chromosomes) and males (who have one X and
one Y chromosome) have two functional copies of the
SHOX gene in each cell. The protein encoded by this
gene is a transcription factor and plays a particularly im-
portant role in the growth and maturation of bones in
the arms and legs. Deletion or duplication of the SHOX
gene is a well-established cause of ISS [19] (MIM300582). Moreover, partial SHOX duplications appeared
to have a more deleterious effect on skeletal dysplasia
and height gain than complete SHOX duplications [19].
In patient 4, a 4q11-q13.1 duplication was detected,
while the other duplication of a smaller region at the
same position (4q12) was identified in patient 5. The
pathogenicity of the large duplication in patient 4 was
evaluated based on the size of the CNV as well as two
genes, TMEM165 and POLR2B. Mutations in the
TMEM165 gene cause congenital disorder of glycosyla-
tion, type IIk in which postnatal growth retardation is a
common symptom [20]. In the DGV database, there
were not any reports of duplications or large deletions in
the region of the gene, implying the rareness of CNVs
comprising the TMEM165 gene. The POLR2B gene en-
codes the second largest subunit of RNA polymerase II
(Pol II), a DNA-dependent RNA polymerase that cata-
lyzes the transcription of DNA into precursors of
mRNA, snRNA and microRNA. It has been shown to
strongly associate with human height in the GWAS
study [10]. Biological pathways analysis showed that
POLR2B protein could interact with OBSL1 protein,
which was associated with one of the commonest prim-
ordial growth disorders, 3-M syndrome [21]. Without
further information, both TMEM165 and POLR2B were
deemed as candidate genes in patient 4. In patient 5, the
PDGFRA gene was one of the 84 genes related to the
JAK/STAT pathway through which growth hormone
promotes cellular growth and proliferation [22]. More-
over, low PDGFRA expression negatively affected the
body size not only in the mice but also in human [23].
This gene encodes platelet-derived growth factor recep-
tor alpha which plays a role in the development of bone
[24, 25]. We suspected that partial duplication of the
PDGFRA gene in patient 5 disrupted the expression of
this gene and contributed to ISS.
In the group of uncertain significance, a 15 kb micro-
deletion found in a seven-year-old boy was of interest.
The heterozygous deletion spanned only the exon 6 to 9
of one gene, the RASA2 gene. The protein encoded by
this gene is a member of the GAP1 family of GTPase-
activating proteins. Acting as a suppressor of RAS func-
tion, the protein enhances the weak intrinsic GTPase
activity of RAS proteins resulting in the inactive GDP-
bound form of RAS, thereby allowing control of cellular
proliferation and differentiation. Causative mutations in
several genes encoding components of the RAS/MAPK
ERK pathway have been demonstrated to result in short
stature, and the group of disorders is termed RASopa-
thies [26]. Noonan syndrome (NS) is one of the RASo-
pathies. Peng-Chieh Chen et al. [27] reported that three
patients of NS carried a different heterozygous mutation
in RASA2 gene, respectively. Moreover, expression of
the mutant RASA2 alleles in heterologous cells increased
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role in NS pathogenesis. As to our patient, he only pre-
sented hyperkeratosis of skin as well as short stature,
which was corresponding to the features of NS. How-
ever, this CNV was validated to derive from his mother
who was normal. As a result, it was classified into VUS.
Conclusions
In conclusion, in the present study, we detected five rare
CNVs as the potential causes of ISS in 119 children. The
applicability of the custom genome-wide microarray was
validated to detect CNVs in patients with short stature,
with a diagnostic yield of 2.5 %. Several candidate genes
were identified to be associated with growth based on
the bioinformatics analyses, and further studies were ne-
cessary to clarify their involvement in the growth path-
ways. A number of CNVs, which were classified to be
benign or VUS, might be useful for further study to
analyze the pathogenicity of CNVs detected in patients
with short stature. Our results expanded the potentially




Patients were selected from the children referred to our
pediatric endocrine clinic due to short stature using the
following criteria [28]: (1) short stature with height
SDS ≤ −2; (2) no obviously abnormal body proportions;
(3) normal length and weight for gestational age at birth;
(4) normal food intake; (5) no evidence of known causes
of short stature [2], including endocrine diseases (growth
hormone deficiency and hypothyroidism), skeletal dys-
plasias and systemic diseases such as Turner syndrome.
The study was approved by the by the ethics commit-
tee of Xinhua Hospital and informed consent form was
obtained from all families.
Chromosome microarray design and testing
The array platform was designed as a 4 × 180 K CGH +
SNP microarray by Agilent Technologies Inc. (Santa
Clara, CA, USA). This array contained ~110,000 oligo-
nucleotide probes for the detection of CNVs, and
~60,000 SNP probes for the detection of loss of hetero-
zygosity (LOH) as well as CNVs. It contained high-
density coverage for 1469 target genes (Additional file 1:
Table S1) with an average oligo probe spacing of ~5 kb
or at least 20 probes per gene. These target genes were
summarized from previous studies [11] and some un-
published data of our own study. In addition, genome-
wide backbone coverage was included with an average
probe spacing of ~25 kb.
Genomic DNA was extracted from peripheral blood
leucocytes of all patients using the standard procedureof the lab. The CMA testing was conducted according to
the manufacturer’s protocol. The results were processed
using the Agilent CytoGenomics Edition 2.9.2.4 software
(Agilent Technologies, Inc.). The adjusted Aberration
Detection Method 2 analysis algorithm was applied for
CNV calling with a sensitivity threshold of 6.0. Briefly, at
least 3 continuous probes were required to call an aber-
ration of a genomic segment as a duplication or a dele-
tion. The log2 ratio of test/reference intensities >0.53
was considered duplication, whereas the ratio <−0.9 was
considered deletion. All the coordinates of CNVs were
based on NCBI human genome build 37 (hg19).
CNVs analysis and validation
All detected CNVs were firstly compared with data in
the Database of Genomic Variants (DGV) [29] to ex-
clude polymorphic CNVs. The remaining CNVs were
preliminarily evaluated for pathogenicity considering the
following conditions [30]: (1) overlap with genomic co-
ordinates for a known genomic imbalance syndrome; (2)
gene content of coding genes associated with impaired
developmental process and/or impaired cell growth
pathways and/or growth impairment in animal models;
(3) more than 3 Mb in size, especially for microdeletion;
(4) overlap with CNVs defined in other patients present-
ing postnatal short stature reported in the Database of
Chromosomal Imbalance and Phenotype in Humans
using Ensembl Resources (DECIPHER) [31]. As a result,
CNVs were classified into four categories: (I) known
pathogenic CNVs (known microduplication or microde-
letion syndromes); (II) possibly pathogenic CNVs in
which there were genes with evidence supporting the
pathogenicity; (III) variants of uncertain significance
(VUS) if they were unable to be classified in one of the
two categories mentioned above; (IV) probably benign if
the CNV was identified in several patients without
pathogenic evidence or there was no gene in the inter-
val. A CNV only involved in non-coding areas was also
thought to be benign.
All type III and IV CNVs were not further assessed.
Type I and II CNVs were validated twice with two pairs
of primers in different genes (Additional file 1: Table S3)
by quantitative real-time polymerase chain reaction
(qPCR) using the SYBR Premix Ex Taq (Tli RNaseH
Plus) kit (Takara Bio Inc., Terra Bella, CA, USA) on a
ViiA7 or StepOnePlus Real-Time PCR System (Life
Technologies, Carlsbad, CA, USA). If the genomic DNA
of the patient’s parents was available, the occurrence (de
novo or inherited) status would be provided.
All validated type I and II CNVs were further evalu-
ated. Gene function was collected from the Online
Mendelian Inheritance in Man (OMIM) and NCBI
Entrez Gene databases. The information regarding gene
involved in growth impairment in mouse model was
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Mouse Genome Informatics (MGI) database [32]. The
function of microRNAs in the CNVs was evaluated using
the miRBase and miRTarBase databases [33, 34].
PubMed and Google Scholar databases were searched to
obtain as much information as possible.
Additional file
Additional file 1: Table S1. List of 1469 height-associated candidate
genes analyzed by genome-wide association studies. Table S2. Summary
of type III and IV CNVs. Table S3. Primers of qPCR. Figure S1.
Screenshots of chromosome microarray and qPCR. (DOC 7216 kb)
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